Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Kunio Okamoto's publication output changed over time?
ScholarIQpublication output · 1988–2015
Output grew0% over the shown period — from 1 works in 1988 to 1 in 2015.
1
1
2
3
3
1
198819902010201120142015
What are the most-cited papers on Kunio Okamoto?
ScholarIQmost cited works
Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection
Yasuhiro Kidera, Hisato Kawakami, Tsutomu Sakiyama, Kunio Okamoto, Kaoru Tanaka, Masayuki Takeda, Hiroyasu Kaneda, Shinichi Nishina, Junji Tsurutani, Kimiko Fujiwara, Morihiro Nomura, Yuzuru Yamazoe, Yasutaka Chiba, Shozo Nishida, Takao Tamura, Kazuhiko Nakagawa
PLoS ONE. 2014128 CitationsOPEN ACCESS
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
Junko Tanizaki, Isamu Okamoto, Kunio Okamoto, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Kazuhiko Nakagawa
Journal of Thoracic Oncology. 2011126 CitationsOPEN ACCESS
Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for <i>EGFR</i> Mutations
Kunio Okamoto, Isamu Okamoto, Wataru Okamoto, Kaoru Tanaka, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Kazuto Nishio, Kazuhiko Nakagawa
Cancer Research. 201081 Citations
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
Hisato Kawakami, Isamu Okamoto, Kimio Yonesaka, Kunio Okamoto, Kiyoko Shibata, Yume Shinkai, Haruka Sakamoto, Michiko Kitano, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa
Oncotarget. 201480 CitationsOPEN ACCESS
Overcoming Erlotinib Resistance in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin
Kunio Okamoto, Isamu Okamoto, Erina Hatashita, Kiyoko Kuwata, Haruka Yamaguchi, Aya Kita, Kentaro Yamanaka, Mayumi Ono, Kazuhiko Nakagawa
S48437117. 201168 Citations
Related on ScholarIQ
Kagawa Prefectural Central Hospital
Institution
Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection
Paper
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
Paper
Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for <i>EGFR</i> Mutations
Paper
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
Paper
Overcoming Erlotinib Resistance in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin
Paper